Advanced Filters
noise

Additional Locations, Massachusetts Clinical Trials

A listing of Additional Locations, Massachusetts clinical trials actively recruiting patient volunteers.

Found 1,769 clinical trials
A Alexandra Touroutoglou, PhD

Transcranial Magnetic Stimulation Treatment for Alzheimer's Disease

In this research study we want to learn more about the effects of non-invasive brain stimulation on memory and brain-network function in cognitively unimpaired older adults and in patients with amnestic mild cognitive impairment (aMCI). This study will use a form of non-invasive brain stimulation called repetitive Transcranial Magnetic Stimulation …

40 - 99 years of age All Phase N/A
P Praful Ravi, MB BChir, MRCP

LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer

The purpose of this study is to see whether the combination of a chemotherapy drug, carboplatin, along with the radioligand treatment, 177Lu-PSMA-617, is safe in treating prostate cancer and whether the combination is effective in shrinking or preventing growth of prostate cancer. The names of the study drugs used in …

18 years of age Male Phase 1
A Aparna Patnaik, BA

Combined Anabolic Therapy

In this research study the study investigators want to learn more about the effect of two different FDA-approved medication regimens in the treatment of postmenopausal osteoporosis.

45 years of age Female Phase 4
D Danielle DeSouza, PhD

Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness

Participants will receive Transcranial Magnetic Stimulation (TMS) at a random location in the left prefrontal cortex, excluding sites that are potentially unsafe. Extensive behavioral testing will be conducted to determine which behaviors are modulated by stimulating which circuits.

18 - 65 years of age All Phase 2
P Panagiotis Konstantinopoulos, MD, PhD

Belzutifan in Recurrent Clear Cell Ovarian Carcinoma

The purpose of this research study is to see if the study drug Belzutifan is effective and safe for participants with ovarian cancer. The name of the study drug involved in this study is: Belzutifan (a type of Hypoxia-Inducible Factor-2 alpha (HIF-2a) inhibitor)

18 years of age Female Phase 2
M Madelaine Nye

Cerebellar Modulation of Cognition in Psychosis

The goal of this clinical trial is to learn about cognition in psychotic disorders (schizophrenia, bipolar disorder, and schizoaffective disorder). The main question it aims to answer is: Can we use magnetic stimulation to change processing speed (how quickly people can solve challenging tasks). Participants will be asked to perform …

18 - 55 years of age All Phase N/A
E Emma Logan, RN

Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy

This research is being done to see if epcoritamab is effective in treating follicular lymphoma as a second line of treatment. The name of the study drug in this research study is: -Epcoritamab (a type of antibody)

18 years of age All Phase 2
D Derek Stenquist, MD

Assessment of the Feasibility of Using a Preoperative Surgical Fracture Analysis Tool

This study aims to evaluate a preoperative fracture analysis tool that uses 3D visualization and biomechanical modeling to assist surgeons in planning screw and plate fixation for complex tibial plateau fractures. By simulating different fixation strategies based on patient-specific CT data, the tool provides insights into construct stability, potentially improving …

18 years of age All Phase N/A
A Alexis Gossett, BSN, RN

KiteLock 4% EDTA Lock Solution for the Prevention of Occlusions in Children with Intestinal Failure

A multi-site, randomized, 2-arm open-label trial to determine if 4% Tetrasodium (EDTA) catheter lock solution is more effective than heparin lock (standard of care) in preventing central venous catheter occlusions in children with intestinal failure (IF) on total parenteral nutrition (TPN).

4 - 18 years of age All Phase N/A

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.

18 years of age All Phase 1

Simplify language using AI